Immunine (Human Coagulation Factor Ix)

Human coagulation factor IX supplied by Immunine binds to activated factor VIII, forming a complex that activates factor X to Xa. This step accelerates thrombin generation, leading to fibrin clot formation and effective hemostasis in individuals lacking sufficient endogenous factor IX.

The dose of Immunine is individualized by the prescribing clinician based on the patient’s measured factor IX activity, severity of bleeding, body weight, and clinical response. No fixed regimen can be provided without a medical assessment.

Safety data for Immunine in pregnancy and lactation are limited. Use is generally reserved for situations where the benefit to the mother outweighs potential risks to the fetus or infant, and decisions should be made by a healthcare professional.

To order Immunine, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Immunine provides recombinant or plasma‑derived human factor IX similar to other licensed concentrates. Differences may lie in manufacturing process, purity, viral inactivation steps, and storage requirements. Clinical efficacy is comparable when dosed appropriately, but specific product attributes should be reviewed with a specialist.

Immunine must be stored refrigerated between 2 °C and 8 °C. Keep the vial in its original packaging, protect from light, and avoid freezing or shaking the product to maintain stability and potency.

Immunine is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and total dose are determined by the prescriber based on the patient’s factor IX level, weight, and clinical situation.

Serious risks include the development of neutralizing inhibitors against factor IX, severe allergic or anaphylactic reactions, and rare thromboembolic events. Patients should be monitored closely for signs of these reactions during and after infusion.

Immunine should not be used in individuals with a known hypersensitivity to human factor IX or any excipients in the formulation. Caution is also advised for patients with a history of inhibitor formation or uncontrolled hypertension.